Mangalam Drugs and Organics Ltd
Incorporated in 1977, Mangalam Drugs
& Organics Ltd manufactures Active Pharmaceutical Ingredients and
Intermediates[1]
- Market Cap ₹ 129 Cr.
- Current Price ₹ 81.6
- High / Low ₹ 145 / 70.1
- Stock P/E 18.7
- Book Value ₹ 93.9
- Dividend Yield 0.00 %
- ROCE 8.20 %
- ROE 4.76 %
- Face Value ₹ 10.0
Pros
- Stock is trading at 0.87 times its book value
Cons
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of 2.42% over past five years.
- Company has a low return on equity of -0.18% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
123 | 221 | 295 | 299 | 269 | 228 | 282 | 380 | 451 | 372 | 369 | 318 | |
113 | 200 | 257 | 252 | 222 | 218 | 259 | 327 | 402 | 347 | 351 | 282 | |
Operating Profit | 10 | 20 | 38 | 47 | 47 | 10 | 24 | 53 | 49 | 26 | 17 | 36 |
OPM % | 8% | 9% | 13% | 16% | 17% | 4% | 8% | 14% | 11% | 7% | 5% | 11% |
0 | 0 | 0 | -0 | 1 | 0 | 1 | 5 | 0 | 0 | 0 | 0 | |
Interest | 10 | 10 | 9 | 10 | 12 | 9 | 10 | 9 | 11 | 13 | 14 | 15 |
Depreciation | 4 | 4 | 4 | 5 | 7 | 7 | 8 | 9 | 10 | 11 | 15 | 16 |
Profit before tax | -4 | 6 | 24 | 31 | 29 | -6 | 6 | 40 | 28 | 2 | -11 | 5 |
Tax % | -22% | -2% | 33% | 29% | 32% | 40% | -32% | 29% | 29% | 43% | -18% | -39% |
-3 | 6 | 16 | 22 | 20 | -8 | 8 | 28 | 20 | 1 | -9 | 7 | |
EPS in Rs | -2.31 | 4.66 | 11.15 | 14.08 | 12.57 | -5.07 | 5.21 | 17.67 | 12.42 | 0.80 | -5.72 | 4.37 |
Dividend Payout % | 0% | 0% | 0% | 0% | 4% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | 4% |
5 Years: | 2% |
3 Years: | -11% |
TTM: | -14% |
Compounded Profit Growth | |
---|---|
10 Years: | 1% |
5 Years: | -4% |
3 Years: | -29% |
TTM: | 177% |
Stock Price CAGR | |
---|---|
10 Years: | 7% |
5 Years: | 4% |
3 Years: | -9% |
1 Year: | -24% |
Return on Equity | |
---|---|
10 Years: | 9% |
5 Years: | 7% |
3 Years: | 0% |
Last Year: | 5% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 13 | 13 | 14 | 16 | 16 | 16 | 16 | 16 | 16 | 16 | 16 | 16 |
Reserves | 10 | 16 | 47 | 70 | 88 | 80 | 88 | 115 | 135 | 136 | 127 | 133 |
77 | 78 | 60 | 66 | 69 | 65 | 52 | 70 | 88 | 89 | 106 | 89 | |
25 | 63 | 38 | 38 | 54 | 50 | 75 | 64 | 90 | 117 | 109 | 121 | |
Total Liabilities | 125 | 170 | 160 | 190 | 227 | 211 | 231 | 264 | 328 | 358 | 357 | 359 |
53 | 53 | 54 | 93 | 102 | 103 | 101 | 118 | 135 | 142 | 147 | 158 | |
CWIP | 0 | 0 | 5 | 0 | 0 | 0 | 1 | 6 | 6 | 9 | 8 | 0 |
Investments | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
72 | 117 | 100 | 95 | 125 | 107 | 128 | 140 | 188 | 206 | 202 | 201 | |
Total Assets | 125 | 170 | 160 | 190 | 227 | 211 | 231 | 264 | 328 | 358 | 357 | 359 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
7 | 14 | 22 | 43 | 25 | 22 | 31 | 28 | 26 | 38 | 12 | 43 | |
-2 | -4 | -11 | -39 | -16 | -9 | -7 | -31 | -27 | -22 | -18 | -19 | |
-5 | -10 | -11 | -3 | -9 | -11 | -23 | 3 | 3 | -17 | 6 | -22 | |
Net Cash Flow | 0 | 1 | -0 | 0 | -0 | 1 | 0 | -1 | 1 | -1 | -0 | 2 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 88 | 73 | 37 | 45 | 61 | 28 | 52 | 52 | 38 | 46 | 28 | 45 |
Inventory Days | 170 | 134 | 85 | 69 | 132 | 175 | 121 | 85 | 139 | 200 | 185 | 303 |
Days Payable | 97 | 128 | 37 | 38 | 82 | 77 | 106 | 63 | 65 | 139 | 124 | 199 |
Cash Conversion Cycle | 161 | 79 | 85 | 75 | 111 | 126 | 67 | 74 | 112 | 107 | 88 | 148 |
Working Capital Days | 122 | 79 | 76 | 70 | 99 | 102 | 66 | 75 | 84 | 93 | 97 | 102 |
ROCE % | 6% | 16% | 29% | 31% | 25% | 2% | 11% | 27% | 18% | 6% | 1% | 8% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
19 May - Newspaper publication for Declaration of financial results for the quarter and year ended 31st March, 2025
-
Approval Of Financial Results For The Quarter And Year Ended 31St March, 2025
17 May - Approved audited financial results FY25; appointed secretarial auditor FY24; auditors gave unmodified opinion.
-
Board Meeting Outcome for Outcome Of Board Meeting Held On 17Th May, 2025 At 5:00 P.M. To Approve Audited Financial Results Of The Company For The Quarter And Year Ended 31St March 2025
17 May - Approved audited financial results for FY 2025; appointed secretarial auditor for FY 2023-24.
-
Board Meeting Intimation for Approval Of Audited Financial Results(Standalone And Consolidated) For The Quarter And Year Ended 31St March, 2025
14 May - Board meeting on May 17 to approve audited results for FY ended March 31, 2025; trading window closed.
-
Announcement under Regulation 30 (LODR)-Change in Management
11 Apr - Appointment of CFO and auditors for FY 2025-26.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2013
from nse
-
Financial Year 2012
from nse
-
Financial Year 2012
from bse
Business Overview:[1]
Company manufactures bulk drugs, organic and inorganic chemicals. It is among the few companies which are World Health Organization -approved Indian companies to be associated with the William J Clinton Foundation for manufacture of anti-malarial drugs. Company supplies artemisinin-based bulk drugs to pharmaceutical companies, for manufacturing anti-malarial formulations